For Immediate Release November 2, 2026

Sumitomo Chemical Announces Revisions to its Financial Forecast and Projected Dividend for the Full Year Ending March 31, 2027

Based on recent performance trends, Sumitomo Chemical (hereinafter, the "Company") has made revisions to its consolidated financial forecast for the full year ending March 31, 2027 and the projected dividend, previously announced on May 14, 2026, as detailed below.

1. Revisions to Consolidated Financial Forecast for the Full Year Ending March 31, 2027 (April 1 2026-March 31, 2027)

(Millions of yen)

	Sales Revenue	Core Operating Income*	Operating Income	Net Income Attributable to Owners of the Parent	Earnings per Share (yen)
Previous forecast (A)	2,360,000	215,000	177,000	70,000	42.40
Revised forecast (B)	2,490,000	270,000	215,000	90,000	54.27
Variance in amount (B-A)	130,000	55,000	38,000	20,000	
Variance in percentage (%)	5.5%	25.6%	21.5%	28.6%	
Results for the full year ended March 31, 2026	2,328,515	208,376	151,744	60,947	37.16

* Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

Reasons for the Revision

Regarding the consolidated financial forecast for FY2026, shipments of semiconductor processing materials in ICT & Mobility Solutions are expected to increase. In Essential & Green Materials, the Company took into account uncertainty in the business environment and incorporated risks into its previous financial forecast, but the Company has made steady progress in its business activities. Additionally, GEMTESA®(therapeutic agent for overactive bladder) sales have increased in North America within Sumitomo Pharma. Therefore, the Company expects sales revenue and core operating income to exceed its previous forecast.

Operating income and net income attributable to owners of the parent are also expected to exceed the previous forecast due to the increase in core operating income.

2. Revision to the Projected Dividend

	Dividend per share		
	Interim	Fiscal year-end	Annual
Previous forecast (Announced on May 14, 2026)		¥8.00	¥16.00
Revised forecast		¥9.00	¥17.00
Actual result	¥8.00		
Previous year results (Fiscal Year Ended March 31, 2026)	¥6.00	¥7.50	¥13.50

Reasons for the Revision

The Company places a high priority on shareholder return and makes it a policy to maintain stable dividend payments, while giving due consideration to its business performance and a dividend payout ratio for each fiscal year and the amount of retained earnings necessary for future growth.
Because of the upward revisions as stated above, the Company decided to revise the projected year-end dividend to ¥9 per share. As a result, the Company's annual dividend will be ¥17 per share.

Cautionary Statement

Statements made in this document with respect to the Company's current plans, estimates, strategies and beliefs that are not historical facts are forward looking statements about the future performance of the Company. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in the Company's markets; demand for, and competitive pricing pressure on, the Company's products in the marketplace; the Company's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

(Supplemental information)

Consolidated Financial Forecast by Segment for Full Year Ending March 31, 2027

(Millions of yen)

		Fiscal 2026 Previous Forecast (A)	Fiscal 2026 Revised Forecast (B)	Variance in Amount (B-A)	Results for the Full Year Ended March 31, 2026
Agro & Life Solutions	Sales revenue	560,000	570,000	10,000	519,256
	Core operating income	65,000	65,000	-	56,334
ICT & Mobility Solutions	Sales revenue	590,000	610,000	20,000	574,162
	Core operating income	55,000	60,000	5,000	53,041
Advanced Medical Solutions	Sales revenue	60,000	60,000	-	58,601
	Core operating income	3,000	3,000	-	2,818
Essential & Green Materials	Sales revenue	560,000	630,000	70,000	678,800
	Core operating income	20,000	75,000	55,000	14,446
Sumitomo Pharma	Sales revenue	540,000	565,000	25,000	451,933
	Core operating income	94,000	108,000	14,000	108,444
Others & Adjustments	Sales revenue	50,000	55,000	5,000	45,763
	Core operating income	(22,000)	(41,000)	(19,000)	(26,707)
Total	Sales revenue	2,360,000	2,490,000	130,000	2,328,515
	Core operating income	215,000	270,000	55,000	208,376